Global Performance Llc Viki... Net Worth

The estimated Net Worth of Global Performance Llc Viki... is at least $745 millió dollars as of 27 June 2019. Global Viki owns over 4,705,900 units of BridgeBio Pharma Inc stock worth over $745,121,538 and over the last 5 years Global sold BBIO stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Global Viki BBIO stock SEC Form 4 insiders trading

Global has made over 1 trades of the BridgeBio Pharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Global bought 4,705,900 units of BBIO stock worth $80,000,300 on 27 June 2019.

The largest trade Global's ever made was buying 4,705,900 units of BridgeBio Pharma Inc stock on 27 June 2019 worth over $80,000,300. On average, Global trades about 4,705,900 units every 0 days since 2019. As of 27 June 2019 Global still owns at least 26,620,991 units of BridgeBio Pharma Inc stock.

You can see the complete history of Global Viki stock trades at the bottom of the page.

Insiders trading at BridgeBio Pharma Inc

Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over $409,396,563 worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth $209,241,115 . The most active insiders traders include Global Investors Lp Viking ..., Andrew Lo és Genetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,173,197. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth $1,554,481.

What does BridgeBio Pharma Inc do?

we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.

Complete history of Global Viki stock trades at BridgeBio Pharma Inc

BridgeBio Pharma Inc executives and stock owners

BridgeBio Pharma Inc executives and other stock owners filed with the SEC include:

• Neil Kumar,
  Chief Executive Officer, Director
• Charles Homcy,
  Chairman of Pharmaceuticals, Lead Director
• Uma Sinha,
  Chief Scientific Officer
• Brian Stephenson,
  Chief Financial Officer
• Eric Aguiar,
  Independent Director
• Ali Satvat,
  Independent Director
• Jennifer Cook,
  Independent Director
• Dr. Neil Kumar Ph.D.,
  Co-Founder, CEO & Director
• Dr. Brian C. Stephenson C.F.A., Ph.D.,
  CFO, Sec. & Principal Accounting Officer
• James Momtazee,
  Independent Director
• Richard Scheller,
  Chairman of Research and Development, Director
• Dr. Michael Thomas Henderson M.D.,
  Chief Bus. Officer
• Dr. Charles J. Homcy M.D.,
  Chairman of Pharmaceuticals & Lead Director
• Dr. Richard H. Scheller Ph.D.,
  Chairman of R&D and Director
• Dr. Cameron Turtle DPHIL, Ph.D.,
  Chief Strategy Officer
• Randal Scott,
  Independent Director
• Brenton Saunders,
  Independent Director
• Andrew Lo,
  Independent Director
• Ronald Daniels,
  Independent Director
• Michael Henderson,
  Chief Business Officer
• Cameron Turtle,
  Senior Vice President - Portfolio Management and Corporate Development
• Frank Mccormick,
  Chairman of Oncology
• Dr. Frank McCormick Ph.D.,
  Chairman of Oncology
• Grace Rauh,
  VP of Communications
• Dr. Uma Sinha Ph.D.,
  Chief Scientific Officer
• Yi Ching Yau,
  Chief Accounting Officer
• Genetic Disorder L.P.Kkr Ge...,
  
• Management Holdings L.P.Kkr...,
  
• Douglas A. Dachille,
  
• Fred Hassan,
  
• Global Performance Llc Viki...,
  
• Global Investors Lp Viking ...,
  
• Genetic Disorder L.P.Robert...,
  
• Yi Ching Yau,
  Chief Accounting Officer
• Brian M. Stolz,
  Chief Operating Officer
• Hannah Valantine,
  
• Brent L Saunders,
  Director
• Andrea Ellis,
  
• Global Investors Lp Viking ...,
  
• Thomas Trimarchi,
  President and COO